Dr. Stephen Chang serves on the Scientific Advisory Board or Board of Directors for GT Biopharma, Orphesus Therapeutics, Cloak Therapeutics, Aegis Therapeutics and Legacy Therapeutics.
Dr. Chang founded Stemgent, Inc. in 2008 and served as the Company’s Chief Scientific Officer. He has been involved in Viagene, Chiron and Canji/Schering Plough in the area of gene and cancer therapy.
Dr. Chang received his PhD in biological chemistry, molecular biology, and biochemistry from the University of California, Irvine and an undergraduate BS from University of Michigan.